Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma

Prieto-Granada C.N. Wiesner T. Messina J.L. Jungbluth A.A. Chi P. Antonescu C.R.

Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.

Am J Surg Pathol. 2016; 40: 479-489Cheah A.L. Billings S.D. Goldblum J.R. Carver P. Tanas M.Z. Rubin B.P.

STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics.

Pathology. 2014; 46: 389-395Doyle L.A. Vivero M. Fletcher C.D. Mertens F. Hornick J.L.

Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.

Mod Pathol. 2014; 27: 390-395Dry SMaF. Leiomyosarcoma S.

WHO classification of Tumours of soft tissue and bone.

5th edition. IARC, 2020: 195-197Cancer Genome Atlas Research Network

Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Cell. 2017; 171: 950-965 e28Barretina J. Taylor B.S. Banerji S. et al.

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

Nat Genet. 2010; 42: 715-721Chibon F. Mairal A. Freneaux P. et al.

The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma.

Cancer Res. 2000; 60: 6339-6345Perot G. Chibon F. Montero A. et al.

Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.

Am J Pathol. 2010; 177: 2080-2090Mentzel T. Calonje E. Wadden C. et al.

Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant.

Am J Surg Pathol. 1996; 20: 391-405Lee A.Y. Agaram N.P. Qin L.X. et al.

Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.

Ann Surg Oncol. 2016; 23: 818-825Fletcher C.D. Gustafson P. Rydholm A. Willen H. Akerman M.

Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.

J Clin Oncol. 2001; 19: 3045-3050Salo J.C. Lewis J.J. Woodruff J.M. Leung D.H. Brennan M.F.

Malignant fibrous histiocytoma of the extremity.

Cancer. 1999; 85: 1765-1772Boughzala-Bennadji R. Stoeckle E. Le Pechoux C. et al.

Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.

Int J Radiat Oncol Biol Phys. 2018; 102: 399-406Look Hong N.J. Hornicek F.J. Raskin K.A. et al.

Prognostic factors and outcomes of patients with myxofibrosarcoma.

Ann Surg Oncol. 2013; 20: 80-86Sanfilippo R. Miceli R. Grosso F. et al.

Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.

Ann Surg Oncol. 2011; 18: 720-725Mutter R.W. Singer S. Zhang Z. Brennan M.F. Alektiar K.M.

The enigma of myxofibrosarcoma of the extremity.

Cancer. 2012; 118: 518-527Haglund K.E. Raut C.P. Nascimento A.F. Wang Q. George S. Baldini E.H.

Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma.

Int J Radiat Oncol Biol Phys. 2012; 82: 361-367Lefkowitz R.A. Landa J. Hwang S. et al.

Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging.

Skeletal Radiol. 2013; 42: 809-818Waters B. Panicek D.M. Lefkowitz R.A. et al.

Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.

AJR Am J roentgenology. 2007; 188: W193-W198Fourman M.S. Ramsey D.C. Kleiner J. et al.

Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence.

Ann Surg Oncol. 2021; https://doi.org/10.1245/s10434-021-10242-4Pisters P.W. Pollock R.E. Lewis V.O. et al.

Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas.

Ann Surg. 2007; 246: 675-681Cahlon O. Brennan M.F. Jia X. Qin L.X. Singer S. Alektiar K.M.

A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation.

Ann Surg. 2012; 255: 343-347Pervaiz N. Colterjohn N. Farrokhyar F. Tozer R. Figueredo A. Ghert M.

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.

Cancer. 2008; 113: 573-581Pasquali S. Pizzamiglio S. Touati N. et al.

The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.

Eur J Cancer. 2019; 109: 51-60Callegaro D. Miceli R. Bonvalot S. et al.

Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.

Lancet Oncol. 2016; 17: 671-680Gronchi A. Ferrari S. Quagliuolo V. et al.

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Lancet Oncol. 2017; 18: 812-822Pasquali S. Palmerini E. Quagliuolo V. et al.

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Cancer. 2022; 128: 85-93Casali P.G. Abecassis N. Aro H.T. et al.

Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018; 29: iv51-iv67Judson I. Verweij J. Gelderblom H. et al.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Lancet Oncol. 2014; 15: 415-423Maki R.G. Wathen J.K. Patel S.R. et al.

Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002.

J Clin Oncol. 2007; 25: 2755-2763Seddon B. Strauss S.J. Whelan J. et al.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Lancet Oncol. 2017; 18: 1397-1410van der Graaf W.T. Blay J.Y. Chawla S.P. et al.

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Lancet. 2012; 379: 1879-1886Tawbi H.A. Burgess M. Bolejack V. et al.

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Lancet Oncol. 2017; 18: 1493-1501Burgess M.A. Bolejack V. Schuetze S. et al.

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

J Clin Oncol. 2019; 37: 11015D'Angelo S.P. Mahoney M.R. Van Tine B.A. et al.

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

Lancet Oncol. 2018; 19: 416-426Roland C.L. Keung E.Z.-Y. Lazar A.J. et al.

Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).

J Clin Oncol. 2020; 38: 11505Okada T. Lee A.Y. Qin L.X. et al.

Integrin-alpha10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.

Cancer Discov. 2016; 6: 1148-1165

留言 (0)

沒有登入
gif